Literature DB >> 23070634

Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study.

Murtaza Emre Durakoğlugil1, Sinan Altan Kocaman, Mustafa Çetin, Aynur Kirbaş, Aytun Canga, Turan Erdoğan, Yüksel Çiçek.   

Abstract

OBJECTIVE: Slow coronary flow (SCF) is an angiographic finding characterized with delayed opacification of epicardial coronary arteries without obstructive coronary disease. CD40/CD40 ligand (CD40L) signaling seems closely related to atherosclerosis due to increased inflammation and prothrombotic state. We investigated whether soluble CD40 (sCD40), an indirect marker of CD40/CD40L dyad, is related to SCF.
METHODS: The present study was cross-sectional and observational, consisting of seventy individuals who underwent coronary angiography with suspicion of CAD and had angiographically normal coronary arteries of varying coronary flow rates. The relationship between sCD40, C-reactive protein (CRP) and SCF phenomenon was investigated. Fifty patients with isolated SCF (mean age: 56±10 years) and 20 age- and gender-matched control participants with normal coronary flow (NCF) and normal coronary arteries (NCA), (mean age: 55±10 years) were included in the study. We used logistic regression analysis to determine the predictors of SCF.
RESULTS: The clinical characteristics were not statistically significant different between SCF and NCA group. Serum CRP levels were also similar between two groups. Serum sCD40 level was significantly higher in the SCF group compared to control group (74±31 vs. 59±16 pg/mL, p=0.014). In multiple regression analyses, mean coronary diameter strongly (OR: 7.358, 95% CI: 1.990-27.20, p=0.003) and sCD40 (OR: 1.044, 95% CI: 1.006-1.084, p=0.023) weakly predicted SCF.
CONCLUSION: This study revealed, significantly increased serum sCD40 levels in patients with SCF. Although we cannot conclude the underlying pathological process of SCF, we believe that these findings may be pivotal for further studies searching the specific roles of CD40/CD40L signaling on SCF phenomenon in coronary vasculature.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23070634     DOI: 10.5152/akd.2013.005

Source DB:  PubMed          Journal:  Anadolu Kardiyol Derg        ISSN: 1302-8723


  6 in total

1.  Interleukin-10 promotor -592A/C polymorphism is associated with slow coronary flow in Han Chinese.

Authors:  Gui-Liang Shi; Xing-Xing Cai; Ya-Min Su; Chu Chen; Xin-Tao Deng; Hai-Yan Pan; Meng-Kan Fan; Jian-Hua Zhu; Min Pan
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

2.  The relationship between eosinophilia and slow coronary flow.

Authors:  Yakup Altas; Ertugrul Kurtoglu; Baris Yaylak; Erkan Baysal; Berzal Ucaman; Hasan Murat Ugurlu; Mehmet Zülkif Karahan; Bernas Altintas; Mehmet Sahin Adiyaman; İlyas Kaya; Umut Erdolu; Kaya Ozen; Cayan Cakir; Utkan Sevuk
Journal:  Ther Clin Risk Manag       Date:  2015-08-12       Impact factor: 2.423

3.  Transcriptional Activity of Gene Encoding Subunits R1 and R2 of Interferon Gamma Receptor in Peripheral Blood Mononuclear Cells in Patients with Slow Coronary Flow.

Authors:  Sanaz Faramarz-Gaznagh; Yousef Rasmi; Mohammad-Hasan Khadem-Ansari; Mir-Hossein Seyed-Mohammadzad; Morteza Bagheri; Mohadeseh Nemati; Alireza Shirpoor; Ehsan Saboori
Journal:  J Med Biochem       Date:  2016-05-09       Impact factor: 3.402

4.  Association of Interleukin-1 Gene cluster polymorphisms with coronary slow flow phenomenon.

Authors:  Ferit Onur Mutluer; Dilek Ural; Barış Güngör; Osman Bolca; Tolga Aksu
Journal:  Anatol J Cardiol       Date:  2018-01       Impact factor: 1.596

5.  Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow.

Authors:  Acar Emrah; İzgi İbrahim Akın; İzci Servet; Kahyaoğlu Muzaffer; Yılmaz Mehmet Fatih; Güler Yeliz; Efe Süleyman Çağan; Güler Ahmet; Kılıçgedik Alev; Kırma Cevat
Journal:  Arch Med Sci Atheroscler Dis       Date:  2016-06-22

6.  Mean platelet volume is not associated with coronary slow flow: a retrospective cohort study.

Authors:  Zekeriya Kaya; Özgür Günebakmaz; Ali Yıldız; Yusuf Sezen; Asuman Biçer Yeşilay; Emre Erkuş; Halil İbrahim Altıparmak; Recep Demirbağ
Journal:  Anatol J Cardiol       Date:  2014-04-02       Impact factor: 1.596

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.